1 completed, 1 terminated, 1 unknown. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Terminated 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow F16IL2: new trials by email Literature Review of F16IL2 trials Research Report on F16IL2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer F16IL2, Nivolumab, fixed dose - Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Unknown | Philogen S.p.A. | 3 | 2017-03-09 | 2022-07-21 |
| Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation F16IL2, BI 836858 - Acute Myeloid Leukemia (AML) Relapse | Phase 1 | Completed | Philogen S.p.A. | 15 | 2016-12-02 | 2022-04-20 |
| A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation F16IL2, cytarabine - Acute Myeloid Leukemia, Relapsed, Adult | Phase 1 | Terminated | Philogen S.p.A. | 30 | 2016-04-13 | 2023-10-10 |
Leukemia, Myeloid, Acute (2) · Recurrence (2) · Carcinoma, Non-Small-Cell Lung (1)
Philogen S.p.A. (3)
Germany (2) · Switzerland (1)